Akero Therapeutics to Present Results from Phase 2b SYMMETRY Study Investigating Efruxifermin in Patients with Compensated Cirrhosis Due to NASH
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/23/2026
- Wall St dips after AI-led selloff; SpaceX worries hit telecoms
- Meta's capital-raising plans expose a major weakness in the AI boom
- Brent crude hits more than five-month high on Houthi-Saudi attacks, UAE oil spill
- BofA flags further downside risk for stocks, yields and dollar
- SpaceX cell-site ambitions lift tower stocks and weigh on carriers
| (NASDAQ: AKRO) | Delayed: 54.74 --0 (-0%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $54.74 | 52 Week High | $ | |||
| Open | $54.74 | 52 Week Low | $ | |||
| Day High | $54.74 | P/E | N/A | |||
| Day Low | $54.74 | EPS | $ | |||
| Volume | 269,010 | |||||
